Physician profile
Daniela E Stamatoiu
NPI 1205971538
$6,561.80
in general payments reported to CMS, 2019-2025
36 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $650 · 2021: $723 · 2022: $1,090 · 2023: $1,106 · 2024: $680 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $388.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,206.78 | 2021-2025 | Vraylar |
| Allergan, INC. | $846.47 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $540.32 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $390.60 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Tris Pharma INC | $347.89 | 2020-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $318.52 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $287.32 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.65 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $275.89 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $257.51 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $237.46 | 2022-2025 | Azstarys |
| Lundbeck LLC | $162.97 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $162.65 | 2019-2023 | Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $150.78 | 2019-2024 | Trintellix |
| Bausch Health US, LLC | $149.01 | 2019-2025 | Aplenzin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $117.36 | 2019-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.08 | 2024 | |
| Ironshore Pharmaceuticals INC. | $87.90 | 2019-2023 | Jornay Pm |
| Eisai INC. | $66.51 | 2020-2021 | |
| Neuronetics, INC. | $59.44 | 2022 | |
| Collegium Pharmaceutical, INC. | $55.98 | 2025 | Jornay Pm |
| Novo Nordisk INC | $49.57 | 2022-2024 | Wegovy, Saxenda |
| Vertical Pharmaceuticals, LLC | $48.06 | 2019-2025 | Relexxii |
| Brainsway USA INC | $45.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $37.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $35.41 | 2021 | |
| Noven Therapeutics, LLC | $35.33 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $31.71 | 2023-2024 | Quviviq |
| Merz North America, INC. | $30.40 | 2022 | |
| Vanda Pharmaceuticals INC. | $29.80 | 2021 | |
| Adlon Therapeutics L.P. | $20.89 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.86 | 2025 | Cobenfy |
| Tempus Ai, INC | $15.05 | 2024 | |
| Shire North American Group INC | $14.58 | 2019 | |
| Alfasigma USA, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Stamatoiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.